Inflammation-related changes in cyclic AMP and cyclic GMP in bovine mastitis

Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) cocentrations in milk and plasma samples from healthy and mastitic cows were determined by radioi-immunoassay and compared with prostaglandins (PGE2, PGF2 and thromboxane B2 [TXB2]), phospholipids and other relevant parameters in milk and blood. The concentrations of cAMP were about five times higher in plasma (p<0.01) than in milk, whereas the cGMP concentration in milk was three times higher (p<0.01) than that in plasma in both healthy and diseased animals. In mastitic milk, the cAMP and cGMP concentrations were 19% and 65% and in blood plasma 13% and 84% higher respectively than in healthy animals. In milk, cyclic nucleotide concentrations correlated with the markedly elevated cell count and also with the prostaglandin concentration and pH. In blood, cAMP correlated positively with phospholipids and cGMP with reduced glutathione (GSH). These changes are considered to be important in the disease process and, in particular, the increase in cGMP deserves further study.     

奶牛隐性乳腺炎病原菌的分离鉴定

用兰州乳房炎试验(LMT)对来自西安市某个牛场的76份奶样作隐性乳房炎检验，并对乳样进行细菌分离鉴定。结果表明，该牛场的隐性乳房炎检出率为33％，阳性乳样中细菌检出率为93．4％。阴性乳样中病原菌检出率为28％，在检出的94株细菌中，共有5种菌22株是与乳房炎有关的病原菌。其中葡萄球菌和链球菌占病原菌总数的90％以上。是引起该场奶牛隐性乳房炎的主要病原菌。     

牛胎儿成纤维细胞分离与体外培养

本研究以 4 5d牛胎儿为材料 ,使用 0 .2 5 %胰酶 + 0 .0 4 %EDTA消化液 ,分离得到牛胎儿成纤维细胞 ,体外培养传代至第 2 8代。本实验描绘出牛胎儿成纤维细胞生长曲线 ,并发现α MEM是一种适合牛胎儿成纤维细胞生长的培养基。分离得到的牛胎儿成纤维细胞传至第 1 8代时核型仍然正常 ,冷冻、解冻后细胞可继续传代     

荷斯坦奶牛隐性乳房炎与乳用特征的相关性分析

随机抽取荷斯坦奶牛 472头 (1～ 11胎 )进行奶牛隐性乳房炎的检测 ,乳用特征性状 (楞角性、尻宽、尻角度、后肢侧视、蹄角度 )的线性评定 ,以及隐性乳房炎与乳用特征的相关性分析。结果表明 :奶牛隐性乳房炎的乳区阳性率与楞角性、尻宽、尻角度、后肢侧视、蹄角度的相关系数分别为 0 1171、0 10 3 0、0 0 681、0 0 180、-0 12 65 ,其中与楞角性、尻宽分别达到显著水平 (P <0 0 5 )的正相关 ,与蹄角度达极显著 (P <0 0 1)的负相关。奶牛阳性率与楞角性、尻宽、尻角度、后肢侧视、蹄角度的相关系数分别为 0 0 967、0 0 5 61、0 0 2 82、0 0 12 7和 -0 0 670 ,其中除与楞角性为显著水平 (P <0 0 5 )的正相关 (0 0 967)外 ,其余均不显著 (P >0 0 5 )。     

Noninferiority trial investigating the efficacy of a nonantibiotic intramammary therapy in the treatment of mild‐to‐moderate clinical mastitis in dairy cows with longer lasting udder diseases

A nonblinded, positively controlled, noninferiority trial was conducted to evaluate the efficacy of an alternative, nonantibiotic therapy with Masti Veyxym^® to reduce ineffective antibiotic usage in the treatment of nonsevere clinical mastitis (CM) in cows with longer lasting udder diseases. The solely intramammary treatment with Masti Veyxym^® (three applications, 12 hr apart) and the combined treatment with Masti Veyxym^® and antibiotics as usual on the farm according to label of the respective product were compared with the reference treatment of solely antibiotic therapy. The matched field study was conducted on eight free‐stall dairy farms located in Eastern Germany. Cases of mild‐to‐moderate CM in cows with longer lasting high somatic cell counts in preceding dairy herd improvement test days and with previous CM cases in current lactation were randomly allocated to one of the three treatment groups. A foremilk sample of the affected quarter was taken before treatment and again approximately 14 days and 21 days after the end of therapy for cyto‐bacteriological examination. Primary outcomes were clinical cure (CC) and no CM recurrence within 60 days after the end of treatment (no R60). Bacteriological cure (BC) and quarter somatic cell count (QSCC) cure were chosen as secondary outcomes although low probabilities of BC and QSCC cure for selected cows were expected. The study resulted in the following findings: the pathogens mostly cultured from pretreatment samples were Streptococcus uberis, followed by Staphylococcus aureus and coagulase‐negative staphylococci. There were no significant differences between the two test treatments in comparison with the reference treatment regarding all outcome variables. The sole therapy with Masti Veyxym^® resulted in a numerically lower likelihood of BC without significant differences to the reference treatment. The combined therapy group showed a numerically higher nonrecurrence rate than the two other treatment groups and noninferiority compared to the reference treatment was proven. Having regard to the selection criteria of cows in this study, the findings indicated that sole treatment with Masti Veyxym^® in nonsevere CM cases may constitute an alternative therapy to reduce antibiotics. However, noninferiority evaluations were mostly inconclusive. Further investigations with a larger sample size are required to confirm the results and to make a clear statement on noninferiority.     

pH对洛美沙星与BSA之间结合常数的影响

[目的]研究洛美沙星与血清白蛋白之间的作用,了解药物分子在体内的运输和分布情况。[方法]采用毛细管区带电泳法,通过测定在不同pH值、不同牛血清白蛋白浓度的缓冲溶液条件下药物迁移时间的变化,计算出洛美沙星与牛血清白蛋白相互作用的结合常数（Kb）。[结果]pH分别为6.8,7.4和8.0时,洛美沙星与BSA之间的Kb分别为10.185×1045、.319×1045、.356×104 L/mol。[结论]环境pH对洛美沙星与BSA之间的相互作用有强烈影响,当pH处在6.8～7.4之间时,Kb对pH尤为敏感。     

表达牛病毒性腹泻病毒E2蛋白的重组乳酸菌的构建及蛋白免疫原性分析

试验旨在构建能表达牛病毒性腹泻病毒（Bovine viral diarrhea virus，BVDV）E2抗原蛋白的重组乳酸乳球菌（Lactococcus lactis），为进一步研制BVDV乳酸菌口服活载体疫苗奠定基础。将BVDV E2基因克隆后测序，根据乳酸乳球菌的密码子偏嗜性进行优化，再将优化的基因片段插入表达载体pNZ8148中，并电转化乳酸乳球菌NZ9000感受态细胞，构建重组乳酸菌pNZ8148-E2/NZ9000，经1 ng/mL乳链菌肽诱导表达后，对菌体物进行了SDS-PAGE和Western blotting分析。将重组乳酸菌pNZ8148-E2/NZ9000口服免疫6~12月龄健康犊牛，在免疫后不同时间点采集血液样品并分离血清，用间接ELISA方法检测抗体水平。结果显示，PCR扩增到了1 149 bp的目的片段，乳酸菌密码子偏嗜性优化后，GC含量从45.28%变为34.30%。重组质粒pNZ8148-E2经酶切鉴定插入片段与预期大小相符，在菌体裂解物中出现大小约42 ku的条带，与预期蛋白大小一致，且该蛋白可与BVDV E2抗体反应。在免疫犊牛的血清中检测到特异性抗BVDV E2蛋白的抗体。本研究结果表明，表达BVDV E2蛋白的重组乳酸菌口服免疫可诱导犊牛产生特异性的体液免疫反应，该重组菌具有较好的免疫原性。     

反向遗传技术在牛轮状病毒研究中的应用

本文综述了牛轮状病毒的生物学特性、反向遗传学系统的建立及其研究进展,并对反向遗传技术应用于牛轮状病毒进行展望。